三氧化二砷治疗真性红细胞增多症的初步研究

In vitro and in vivo effects of arsenic trioxide on polycythemia vera

在观察As2O3 对K562细胞系和真性红细胞增多症(PV)患者外周血单个核细胞的体外效应的基础上 ,分析As2O3 治疗3例PV患者的临床结果。方法 :以K562细胞和PV患者的新鲜细胞为体外靶子 ,通过细胞形态学、流式细胞仪和Annexin V的测定检测细胞凋亡。每日静脉滴注10ml0 1 %As2O3 注射液治疗3例PV患者 ,至完全缓解停药并继续随访。结果 :1～2μmol/LAs2O3 注射液诱导K562细胞和3例PV患者的外周血单个核细胞凋亡。临床研究显示 ,经As2O3 治疗 ,病人的血红蛋白和白细胞水平分别从1～6周和第1周起开始明显下降。外周血血小板水平较用药前有所降低 ,但均在正常范围内。3例患者均达缓解 ,并未出现骨髓抑制。结论 :As2O3

Objective: To understand possible therapeutic efficacy of arsenic trioxide (As2O3) in polycythemia vera (PV) through in vitro analyzing effects of As2O3 on K562 cells and fresh cells from PV patients Methods:K562 cellline and fresh mononuclear cells from peripheral blood of 3 PV patients were used in this study Cell apoptosis was assessed by means of morphology,flow cytometry and Annexin V assay Three PV patients were treated with the intravenous transfusion of 10 ml 0 1%As2O3 every day until remission Results: As2O3 inconcentration of 1 to 2 μmol/L induced cell apoptosis in K562 cells and freshcells from PV patients Clinical observation showed that with As2O3 treatment, hemoglobin and peripheral white blood cell counts of the patients were decreasedgradually from 1 6 weeks and 1 week,respectively Peripheral platelet counts were also reduced but in the normal range All three patients archived remissionwithout bone marrow suppression Conclusion: As2O3 could have clinical efficacy for treatment of PV patients